Cargando…

Safety and Effectiveness of Molnupiravir (LAGEVRIO(®)) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan

INTRODUCTION: Molnupiravir is an oral antiviral drug that received special approval for emergency use in Japan on December 24 2021 for infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This post-marketing surveillance (PMS) is underway to investigate the safe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimata, Masahiro, Watanabe, Asuka, Yanagida, Yukiko, Kinoshita, Daisuke, Maekawa, Shinichiroh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018610/ https://www.ncbi.nlm.nih.gov/pubmed/36928787 http://dx.doi.org/10.1007/s40121-023-00782-5

Ejemplares similares

Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan
por: Hiraishi, Itaru, et al.
Publicado: (2021)

2704. Real-world safety and effectiveness of letermovir for preventing cytomegalovirus (CMV) disease in patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT): Final results of post-marketing surveillance (PMS) in Japan
por: Fukuda, Masaki, et al.
Publicado: (2023)

Real‐world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all‐case postmarketing surveillance in Japan
por: Yamazaki, Naoya, et al.
Publicado: (2022)

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
por: Nishiyama, Hiroyuki, et al.
Publicado: (2023)

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study
por: Yasaka, Masahiro, et al.
Publicado: (2020)

Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2022)

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan
por: Saida, Takahiko, et al.
Publicado: (2017)

Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
por: Yokoyama, Seiji, et al.
Publicado: (2021)

Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study
por: Yoshikawa, Ken, et al.
Publicado: (2020)

Efficacy of Paxlovid and Lagevrio for COVID-19 Infection in Patients With Inflammatory Bowel Disease: A Propensity-Matched Study
por: Hashash, Jana G., et al.
Publicado: (2023)

Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan
por: Hongo, Haruyuki, et al.
Publicado: (2021)

Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
por: Murai, Hiroyuki, et al.
Publicado: (2021)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
por: Nakamura, Shiro, et al.
Publicado: (2022)

Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
Publicado: (2021)

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
por: Kato, Hideki, et al.
Publicado: (2018)

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
por: Ito, Shuichi, et al.
Publicado: (2018)

Real‐world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12‐week interim analysis of post‐marketing surveillance in Japan
por: Hayashi, Nobukazu, et al.
Publicado: (2022)

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
por: Ogura, Takashi, et al.
Publicado: (2023)

Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

537. Safety and Effectiveness of Ensitrelvir for the Treatment of COVID-19 in Japanese Clinical Practice: A Post-marketing Surveillance (Interim Analysis)
por: Ogura, Eriko, et al.
Publicado: (2023)

Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan
por: Sagara, Rieko, et al.
Publicado: (2021)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice: interim data from post-marketing surveillance in Japan
por: Tanabe, Nobuhiro, et al.
Publicado: (2020)

Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
por: Nakamura, Ichiro, et al.
Publicado: (2019)

Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients
por: Kadowaki, Takashi, et al.
Publicado: (2018)

Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation
por: Teshima, Yasutomo, et al.
Publicado: (2020)

Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance
por: Kuroishi, Naho, et al.
Publicado: (2019)

Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
por: Nakazawa, Toru, et al.
Publicado: (2022)

Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
por: Nakamura, Ichiro, et al.
Publicado: (2021)

Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study
por: Tanihara, Hidenobu, et al.
Publicado: (2020)

Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study
por: Tanihara, Hidenobu, et al.
Publicado: (2019)

A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19
por: Nakamura, Keisuke, et al.
Publicado: (2022)

Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study
por: Kaneda, Hiroyasu, et al.
Publicado: (2020)

Correction to: Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study
por: Tanihara, Hidenobu, et al.
Publicado: (2020)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database
por: Okuda, Shoki, et al.
Publicado: (2023)

Japanese Physicians’ Views on Drug Post-Marketing Surveillance
por: Maeda, Kazuki, et al.
Publicado: (2015)

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world practice: Results of 12‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)
por: Utsunomiya, Kazunori, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n78spc05ti4p9fdmaeioa6p6ve